A 2026 informational consumer research report analyzing CardioGLYX Blood Support marketing claims, ingredient research context, pricing disclosures, and verification considerations for adults ...

Children with hypertriglyceridemia treated with fenofibrate had lower levels of triglycerides, low-density lipoprotein cholesterol, and total cholesterol than those treated with omega-3 fatty acids.

Results from a blood test can be filled with unrecognizable words. For example, you may wonder what it means if the results say you have high triglycerides. Triglycerides are a type of fat that ...

The triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio reflects the balance between atherogenic and anti-atherogenic lipid fractions. The study aims to investigate the utility of ...

What Is Redemplo, and Why Does It Matter? Redemplo (plozasiran) is a type of medicine called a small interfering RNA (siRNA) therapy approved to help lower extremely high triglyceride levels in adults ...

The FDA approved plozasiran (Redemplo) for the reduction of triglycerides in people with familial chylomicronemia syndrome (FCS), the agency announced. The small interfering RNA (siRNA) therapy, ...

Redemplo, an siRNA medication, targets APOC3 to reduce triglycerides in familial chylomicronemia syndrome (FCS) patients, lowering pancreatitis risk. The PALISADE study showed an 83% reduction in ...

Plozasiran is the first FDA-approved drug for familial chylomicronemia syndrome, reducing triglycerides as an adjunct to diet. The phase 3 PALISADE trial showed significant triglyceride reduction with ...

ByHeart, a manufacturer of organic baby formula, recalled all of its products sold nationwide Tuesday, days after some batches were recalled in an expanding outbreak of infant botulism. At least 15 ...

In a world-first trial, scientists used a one-off CRISPR gene edit to switch off a liver “fat brake” gene, slashing stubborn LDL cholesterol and triglycerides in patients whose levels refused to budge ...

Ionis is planning a supplemental submission by the end of the year to expand Tryngolza into severe hypertriglyceridemia. If granted, William Blair expects the antisense drug to be “transformational” ...